Free cash flow burn has accelerated significantly, with quarterly outflows reaching $92.4 million in 2026Q1 compared to $30.2 million in 2023Q4, reflecting the intensifying capital requirements of its pipeline.
| Cash from Operations | -312.79M | -275.21M | -185.06M | -99.74M | -64.97M | -40M | -14.95M | -9.64M |
| Operating CF Margin % | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -226.71% | -48.71% | -85.55% | -53.51% | -62.43% | -167.58% | -55.09% | - |
| Net Income | -450.07M | -425.38M | -260.76M | -126.22M | -81.85M | -46.34M | -14.56M | -11.81M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | -373K | 215K | 0 | 0 |
| Stock-Based Compensation | 22.07M | 0 | 60.58M | 25.56M | 10.32M | 3.55M | 729K | 41K |
| Deferred Taxes | 0 | 0 | 0 | 0 | -5.74M | -215K | 0 | 0 |
| Other Non-Cash Items | 121.07M | 130.96M | 3.27M | -10.11M | 5.74M | 846K | -2.39M | 1.57M |
| Working Capital Changes | -5.85M | 19.21M | 11.84M | 11.03M | 6.93M | 1.94M | 1.27M | 562K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -4.03M | 24.6M | -4.05M | 2.17M | 4.21M | 1.64M | 529K | 424K |
| Cash from Investing | -168.91M | -124.08M | -573.51M | -143.53M | -10.66M | -220.03M | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 520.59M | 515.34M | 568.88M | 336.85M | 248.92M | 318.22M | 22.27M | 0 |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 284K | -250K | 0 |
| Equity Issued (Net) | 520.59M | 515.34M | 569.99M | 324.3M | 248.63M | 321.92M | 22.5M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -1.1M | 12.55M | 286K | -3.98M | 15K | 0 |
| Net Change in Cash | 38.9M | 116.05M | -189.7M | 93.58M | 173.28M | 58.19M | 7.32M | -9.64M |
| Free Cash Flow | -312.79M | -275.21M | -185.06M | -99.74M | -64.97M | -40M | -14.95M | -9.64M |
| FCF Margin % | - | - | - | - | - | - | - | - |
| FCF Growth % | -53.48% | -48.71% | -85.55% | -53.51% | -62.43% | -167.58% | -55.09% | - |
| FCF per Share | -3.98 | -3.79 | -2.79 | -1.71 | -1.31 | -1.84 | -0.65 | -0.20 |
| FCF Conversion (FCF/Net Income) | 0.69x | 0.65x | 0.71x | 0.79x | 0.79x | 0.86x | 1.03x | 0.82x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical trial execution risk
According to the company's reported financial statements, the gap between net loss and operating cash flow remains significant, with the firm reporting an operating cash outflow of $92.4 million in 2026Q1, a substantial increase from the $30.2 million outflow observed in 2023Q4.
The persistent divergence between net loss and operating cash flow suggests that non-cash expenses, particularly stock-based compensation, are playing a material role in the company's reported bottom line. Investors should monitor whether this cash burn rate continues to accelerate as the company moves deeper into resource-intensive pivotal clinical trials.
As reported in recent quarterly filings, Nuvalent's free cash flow trajectory has deteriorated, with outflows reaching $92.4 million in 2026Q1 compared to $30.2 million in 2023Q4, reflecting the intensifying capital requirements of its late-stage clinical development pipeline.
The consistent negative free cash flow is a structural reality for a pre-revenue biotech, but the trend of increasing quarterly outflows warrants further investigation into the company's runway. This trajectory suggests that the firm is prioritizing clinical speed over near-term cash preservation, which may necessitate future equity financing.
Based on the provided financial data, working capital changes have been inconsistent, swinging from a $12.9 million outflow in 2026Q1 to an $11.9 million inflow in 2025Q3, which appears to be driven by the timing of clinical trial-related payments and vendor obligations.
These fluctuations suggest that the company's cash position is sensitive to the timing of milestone-based payments to clinical research organizations. Analysts should interpret these swings as operational noise rather than a fundamental shift in the company's ability to manage its short-term liabilities.
As evidenced by historical data, stock-based compensation has been a consistent feature of the company's expense structure, reaching $22.1 million in 2025Q2, which effectively obscures the true cash-based operational deficit inherent in the firm's current clinical-stage business model.
While stock-based compensation is a standard tool for talent retention in biotechnology, its magnitude relative to the total cash burn suggests that the reported net loss may understate the actual economic cost of operations. Investors should focus on the cash-based burn rate to assess the true sustainability of the company's current financial position.
Quick answers to the most common questions about buying NUVL stock.
Nuvalent, Inc. (NUVL) generated $-275.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Nuvalent, Inc. (NUVL) reported negative free cash flow of $275.2M in 2025, indicating capital requirements exceeded cash from operations.
Nuvalent, Inc. (NUVL) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.